ZYBERNO
Stock Report
Updated Jun 7, 2026

KYNTRA BIO, INC. (FGEN)

Healthcare • NASDAQ

$6.97

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
KYNTRA BIO, INC. (FGEN) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (-602.1%)
Return on Capital (Capital Efficiency):CRITICAL (-46.3%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

KYNTRA BIO, INC. (FGEN) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, FGEN generated -$21.40M in Owner Earnings. Capital was deployed as follows: $22.00K invested in capital expenditures. Reinvestment rate: 289.6%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:6.97
Market Cap:$28.21M

Valuation Multiples (3)

P/S Ratio:3.79x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$8.71M
B. Profitability Assessment

Return Metrics (4)

ROA:118.1%
Reinvestment Rate:289.6%
Fundamental Growth Rate (g):-134.0%

Margin Analysis (3)

Operating Margin Ttm:-602.1%
Net Margin Ttm:2,159.6%
Ebitda Margin:-596.8%

TTM Performance (3)

Gross Margin Ttm:40.7%
Operating Margin Ttm:-602.1%
Net Margin Ttm:2,159.6%

Yield Metrics (2)

Earnings Yield:$570.01
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-213.2%
Latest Earnings Filed:2026-05-12

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-50.0%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:3.61x
Quick Ratio:3.48x
Cash Ratio:1.32x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-5.14x
Times Interest Earned:-5.14

Capital Structure (4)

Working Capital:73,241,000.00
Cash And Cash Equivalents:36,997,000.00
Long Term Debt:$76.00K
Net Debt:-$36.92M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $7.44M
Linear Growth: -50.0%
📊 Click to view full FGEN Revenue analysis & methodology →
Cost Of Revenue Ttm:$4.41M

Profitability Breakdown (2)

Gross profit TTM: $3.03M
Linear Growth: -50.0%
📊 Click to view full FGEN Gross Profit analysis & methodology →
-$44.79M

Bottom Line Performance (3)

$160.65M
Income Before Tax:-$56.66M
Ebitda Ttm:-44,398,000.00

Operating Expenses (5)

Operating Expenses:52,232,000.00
R And D Expense:21,908,000.00
Sga Expense:25,465,000.00
Income Tax Expense:-$92.00K
Interest Expense:8,929,000.00

Expense Ratios (3)

R And D To Revenue Percentage:586.1%
Sga To Revenue Percentage:681.2%
Ebitda Margin:-596.8%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$109.63M
Current Assets:$101.36M
Ppe Net:0.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:140,399,000.00
Current Liabilities:28,114,000.00
Long Term Debt:$76.00K
Short Term Debt:$0.00

Equity & Capital (3)

Equity:-$30.77M
Retained Earnings:-$1.72B
Common Stock:225,000,000.00

Working Capital Items (3)

Accounts Receivable:5,040,000.00
Inventory:3,384,000.00
Accounts Payable:17,340,000.00

Special Items (2)

Contract Liabilities:5,680,000.00
Stock Based Compensation:1,151,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$21.38M-$21.40M

Investment Activities (2)

Investing Cash Flow:$3.02M
Capital Expenditures Ttm:22,000.00

Financing Activities (3)

Financing Cash Flow:-$7.00K
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:139,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:395,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):39.73
$39.73
Earnings Per Share Ttm:$39.70

Revenue & Cash Per Share (2)

Sales Per Share Ttm:1.84
Operating Cash Flow Per Share:-$1.18

Book Value & Capital (2)

Book Value Per Share:-$7.60
Cash Per Share:9.14

Dividend Policy (1)

Dividend Payout Ratio:0.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.05x
Working Capital Turnover Ttm:0.10x

Receivables Management (2)

Receivables Turnover Ttm:1.48x
Days Sales Outstanding Ttm:247.29

Inventory Management (2)

Inventory Turnover Ttm:1.30x
Days Inventory Outstanding Ttm:280.08

Payables & Cash Cycle (2)

Days Payable Outstanding:1,435.17
Cash Conversion Cycle:-907.80
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:60.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$21.40M

Damodaran Growth Analysis (2)

Reinvestment Rate:289.6%
Fundamental Growth Rate (g):-134.0%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-50.0%

Other Growth Rates (1)

Gross Profit Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:FGEN
Company Name:KYNTRA BIO, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:4.05M
Shares Outstanding Basic:4.05M
Shares Outstanding Diluted:4.05M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-06-07 02:02:28 UTC
Data Timestamp:2026-06-07T02:02:28.476662
Scroll to Top